ADICET BIO INC's ticker is ACET and the CUSIP is 007002108. A total of 91 filers reported holding ADICET BIO INC in Q1 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $867,263 | -43.6% | 632,954 | -0.0% | 0.00% | – |
| Q2 2023 | $1,538,114 | -55.9% | 632,969 | +4.4% | 0.00% | – |
| Q1 2023 | $3,491,648 | +66092.4% | 606,189 | +2.7% | 0.00% | -100.0% |
| Q4 2022 | $5,275 | -99.9% | 590,156 | +9.6% | 0.00% | 0.0% |
| Q3 2022 | $7,657,000 | +24.4% | 538,495 | +27.7% | 0.00% | 0.0% |
| Q2 2022 | $6,154,000 | -21.3% | 421,568 | +7.6% | 0.00% | 0.0% |
| Q1 2022 | $7,824,000 | +45.0% | 391,835 | +27.0% | 0.00% | 0.0% |
| Q4 2021 | $5,396,000 | +102.9% | 308,521 | -9.1% | 0.00% | – |
| Q3 2021 | $2,660,000 | -18.8% | 339,360 | +6.6% | 0.00% | – |
| Q2 2021 | $3,275,000 | +109.9% | 318,341 | +166.8% | 0.00% | – |
| Q1 2021 | $1,560,000 | +231.9% | 119,315 | +256.4% | 0.00% | – |
| Q4 2020 | $470,000 | +37.4% | 33,476 | +16.2% | 0.00% | – |
| Q3 2020 | $342,000 | – | 28,821 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 728,944 | $998,653 | 0.37% |
| DAFNA Capital Management LLC | 797,054 | $1,091,964 | 0.34% |
| COWEN AND COMPANY, LLC | 2,715,278 | $3,719,930 | 0.26% |
| Orbimed Advisors | 8,322,140 | $11,401,332 | 0.24% |
| TANG CAPITAL MANAGEMENT LLC | 1,226,352 | $1,680,102 | 0.24% |
| Carlyle Group Inc. | 2,115,385 | $2,876,924 | 0.12% |
| RTW INVESTMENTS, LP | 4,241,472 | $5,810,817 | 0.12% |
| Acuitas Investments, LLC | 136,779 | $187,387 | 0.11% |
| Decheng Capital Management III (Cayman), LLC | 200,201 | $274,275 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 142,168 | $195 | 0.02% |